Publications

A clinical practice comparison of patients with CLL/SLL with and without del(17p) receiving first-line treatment with ibrutinib →

Hedrick, E, Mato, A, Sharman, J, Tang, B, Azmi, S, Pinilla-Ibarz, J, Yang, K, Stern, J, Huang, J

December 2020

Abstract

American Society of Hematology Annual Meeting

Real-world IgG testing frequency and characteristics associated with hypogammaglobulinemia after anti-CD20 exposure in patients with chronic lymphocytic leukemia →

Hooley, IJ, Maignan, K, Jacob, A, Medina, A, Benderoff, L, Chen, R, Huntington, SF

December 2020

Abstract

American Society of Hematology Annual Meeting

Flatiron-authored

Utilization and early discontinuation of first-line ibrutinib for patients with chronic lymphocytic leukemia treated in the community oncology setting in the United States →

Huntington, SF, Soulos, PR, Barr, P, Jacobs, R, Lansigan, F, Odejide, OO, Schwartzberg, L, Davidoff, AJ, Gross, CP

December 2019

Abstract

American Society of Hematology Annual Meeting

Development and initial validation of a prognostic score based on structured data from EHRs →

Backenroth D, Haimson JD, Meropol NJ, Baxi SS.

April 2019

Abstract

AACR Annual Meeting

Flatiron-authored

Hepatitis B Testing Rates in Patients with Chronic Lymphocytic Leukemia before and during Administration of Anti-CD20 Therapy →

Hooley I, Chen R, Maignan K, Carson K

December 2018

Abstract

Blood Journal

Flatiron-authored

Process Mining for Exploring Treatment Patterns in Chronic Lymphocytic Leukemia (CLL) in a Real World Oncology Database →

Black J, Castro F, Lundberg L, Marino M, Niks R, Rozinat A

August 2018

Abstract

International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE)

Real-World Characteristics of CLL Patients Receiving Front-Line Therapy, Using the Flatiron Health Database →

Tang B, Szabo E, Zhou J, Wu J, Brander D

December 2017

Abstract

American Society of Hematology Annual Meeting

Sequencing Therapy in Chronic Lymphocytic Leukemia (CLL): Treatment Patterns and Associated Outcomes in Community Practice for Patients with Relapsed/Refractory CLL in the United States →

Kapustyan T, Keim H, Meissner B, Nielsen J, Zhang L, Jiang D

December 2017

Abstract

American Society of Hematology Annual Meeting

Clinical and Demographic Characteristics of Cll Patients Receiving First-line Bendamustine Plus Rituximab Using the Flatiron Health Database →

Tang B, Gabriel S, Pathak A, Brander D, Zhou J

June 2017

Abstract

ASCO Annual Meeting

Evidence of Low Incidence of Myelodysplastic Syndrome (MDS) in Patients Exposed to Bendamustine Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) →

Burke J, Bibeau K, Kahl B, Carson K, Zelentz A, Brander D, Maddocks K, Gerecitano J, Pathak A, Cheson B

June 2017

Abstract

ASCO Annual Meeting

Flatiron-authored

Changing Demographics and Treatment Patterns in Patients in the United States with Chronic Lymphocytic Leukemia in the First-line Setting as Assessed Using a Novel Electronic Health Record Database →

Arnieri B, Bernaards C, Wilhelm K, Black J, Hirst C, Taylor M, Lambert P, Green K, Lu M, Humphrey K

December 2016

Abstract

American Society of Hematology Oncology